Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

  • There is currently no data for DEMG

Grant of options

12 Jun 2009 09:22

RNS Number : 8037T
Deltex Medical Group PLC
12 June 2009
 



Deltex Medical Group plc

Grant of options

12 June 2009 - Deltex Medical Group plc ("the Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that the Board has today approved the issue of share options to its executive members.

Employee Share Option Scheme

The Board has approved the issue of contractual share options to Andy Hill, Chief Executive, and Ewan Phillips, Finance Director, under the Company's 2001 Executive Share Option Scheme as follows:

Name

Number

Exercise

Price £

Exercise period 

Total Number of options held

 

 

 

 

 

Andy Hill

500,000

0.1275

2012 - 2019

2,600,000

 

 

 

 

 

Ewan Phillips

500,000

0.1275

2012 - 2019

2,480,000

EMI scheme - Cash bonus sacrifice

In addition, the Company's 2003 Enterprise Management Incentive Scheme ('EMI Scheme') allows directors and employees who have earned performance related bonus payments under the terms of their employment to sacrifice their entitlement to cash payment in return for share options at the nominal value of 1p per share. The EMI Scheme is designed to allow managers to align their interests with those of shareholders by building a meaningful equity interest in the Company while preserving the Company's cash resources for investment in its operations. In the event that the share price on exercise and sale of an EMI Scheme option share is higher than at the date of bonus sacrifice, the EMI Scheme is potentially tax efficient for the scheme member. However, if the share price on exercise and sale of an EMI Scheme option share is lower than at the date of award, the individual will realise an amount after tax that is lower than the amount of bonus originally sacrificed.

Andy Hill and Ewan Phillips have both elected to sacrifice the whole of the performance bonuses (£60,000 each) awarded by the Company's Remuneration Committee in respect of the year ended 31 December 2008, resulting in awards of options under the EMI Scheme as follows

 

Name

Number

Exercise

Price £

Exercise period 

Total Number of options held

 

 

 

 

 

Andy Hill

510,638

0.01

2009 - 2019

1,583,696

 

 

 

 

 

Ewan Phillips

510,638

0.01

2009 - 2019

2,088,754

 

 Additional interest

Mr Hill also has a beneficial interest in 179,334 ordinary shares in the Company representing 0.18 per cent of the issued ordinary share capital of the Company.

 

Mr Phillips also has a beneficial interest in 977,156 ordinary shares in the Company representing 0.96 per cent of the issued ordinary share capital of the Company.

All shares and options relate to ordinary 1p shares

For further information, please contact:-

Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman  Andy Hill, Chief Executive Ewan Phillips, Finance Director

Nominated Adviser and Broker 0207 398 1600

Arden Partners plc

Christopher Hardie

Matthew Armitt

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSIIFFTRIIFLIA
Date   Source Headline
27th Feb 20237:00 amRNSConvertible loan notes repayment date extension
24th Jan 20237:00 amRNSYear end trading update
22nd Dec 20227:00 amRNSYear end update
20th Sep 20227:00 amRNSInterim Results
14th Jul 20227:00 amRNSCompletion of Nominated Adviser due diligence
7th Jul 20227:00 amRNSHalf year trading update
18th May 20223:41 pmRNSResult of AGM
18th May 20227:00 amRNSChairman's Statement to Annual General Meeting
28th Apr 20227:00 amRNSChange of Adviser
7th Apr 20227:00 amRNSResults for the year ended 31 December 2021
2nd Mar 20224:30 pmRNSHolding(s) in Company
17th Feb 20224:02 pmRNSGrant of options
8th Feb 20227:00 amRNSSubscription and extension of Debt Facility
26th Jan 20227:00 amRNSContract win in the Americas
12th Jan 20227:00 amRNSIssue of Equity
11th Jan 20227:00 amRNSPre-close statement
20th Dec 20217:00 amRNSSuccessful Innovate UK Smart Award
20th Sep 20217:00 amRNSInterim results to 30 June 2021
22nd Jul 20213:48 pmRNSIssue of Equity
16th Jul 20217:00 amRNSIssue of Equity
8th Jul 20217:00 amRNSPre-close trading update
30th Jun 20212:06 pmRNSPosting of Accounts
28th May 20217:00 amRNSResult of AGM
27th May 20217:00 amRNSAGM Statement
28th Apr 20217:00 amRNSGrant of options
22nd Apr 20217:00 amRNSResults for the year ended 31 December 2020
13th Apr 202112:30 pmRNSNotice of results, AGM and investor presentation
30th Mar 202112:38 pmBUSEarly Repurchase - Replacement
29th Mar 202110:06 amBUSEarly Repurchase
9th Feb 202110:31 amRNSDirector Dealing
20th Jan 20217:00 amRNSPre-Close Statement and Director Appointment
5th Jan 20211:21 pmRNSHolding(s) in Company
24th Dec 20209:30 amRNSHolding(s) in Company
21st Dec 20207:00 amRNSUpdate on commercial activity and issue of equity
22nd Sep 20204:03 pmRNSDirector Dealing
21st Sep 20207:00 amRNSInterim results to 30 June 2020
3rd Aug 20209:38 amRNSHolding(s) in Company
22nd Jul 20207:00 amRNSGrant of Options
14th Jul 20209:17 amRNSHolding(s) in Company
9th Jul 20207:00 amRNSPre-close Trading Update
17th Jun 20205:00 pmRNSPosting of Accounts
3rd Jun 20203:43 pmRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSResults for the year ended 31 December 2019
24th Apr 20203:39 pmRNSNotice of Results
6th Apr 20202:06 pmRNSSecond Price Monitoring Extn
6th Apr 20202:00 pmRNSPrice Monitoring Extension
12th Mar 202012:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.